

# **INNOVATIONS IN MEDICAL IMAGING**

**Technological advances, growth  
opportunities and future market  
outlook**

***By Dr Cheryl L Barton***

## **Dr Cheryl L Barton**

Dr Cheryl L Barton is an independent consultant with over 16 year's research and business analysis experience. Following her senior research positions in academia and seven years with Merck, in which she was responsible for research projects ranging from Alzheimer's disease to schizophrenia, Dr Barton joined Dutch investment bank ABN Amro NV as a senior equity analyst. At ABN Amro NV she was lead analyst on several pan-European companies, and assessed the potential impact of new drug development on European Stocks.

In 2002, Dr Barton founded a consulting business ([www.Pharmavision.co.uk](http://www.Pharmavision.co.uk)) to provide independent, tailor-made, pharmaceutical thematic research to investment houses and pharmaceutical companies. The research reports combine independent scientific analysis with patient-based models to forecast the potential sales growth of key drugs in clinical development.

Copyright © 2009 Business Insights Ltd  
This Management Report is published by Business Insights Ltd. All rights reserved.  
Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## Innovations in medical imaging

<b>Executive Summary</b>	<b>10</b>	
<b>Introduction</b>	<b>10</b>	
<b>Current issues in medical imaging &amp; recent breakthroughs</b>	<b>11</b>	
<b>Challenges, opportunities &amp; regulations</b>	<b>11</b>	
<b>Market, trends &amp; future directions</b>	<b>12</b>	
<b>Chapter 1</b>	<b>Introduction</b>	<b>16</b>
<b>What does medical imaging encompass?</b>	<b>17</b>	
Anatomical & functional imaging	20	
<b>Why is medical imaging of value to the pharmaceutical industry?</b>	<b>21</b>	
<b>Applications of medical imaging in drug R&amp;D</b>	<b>23</b>	
<b>Leading imaging modalities</b>	<b>26</b>	
X-Ray	27	
Computed tomography	28	
Magnetic resonance imaging	30	
Functional MRI	31	
Optical near-infrared fluorescence imaging	32	
Ultrasound	34	
<b>Nuclear medicine</b>	<b>35</b>	
Positron Emission Tomography	35	
Single Photon Emission Computed Tomography	38	
Other imaging modalities	40	
Video imaging	40	
<b>Comparison of imaging modalities: in vivo &amp; ex vivo applications</b>	<b>41</b>	
<b>Advantages &amp; disadvantages of imaging modalities</b>	<b>42</b>	
<b>Therapeutic applications</b>	<b>43</b>	
Cancer	44	
Breast cancer	45	
Colorectal cancer	46	
Cardiovascular disease	46	
Coronary artery disease	46	
Stroke	47	

Other cardiovascular conditions	47
Gastrointestinal conditions	48
Orthopedics & osteoporosis	48
CNS and thoracic trauma	48
Therapeutic conclusions	48

## **Chapter 2                      Current issues in medical imaging & recent breakthroughs                      52**

Pre-processing & post-processing issues	53
Artifacts	54
Noise	58
Noise & artifact reduction	58
Raw data acquisition & image reconstruction	58
Image enhancement & portioning	59
<b>Conclusions on imaging issues</b>	<b>60</b>
<b>Breakthroughs in medical imaging</b>	<b>60</b>
Novel imaging agents	62
CT imaging agents	62
MRI imaging agents	63
Ultrasound imaging agents	64
PET & SPECT imaging agents	65
Imaging agent conclusions	67
Novel scintillator & detectors	68
Multimodality imaging devices	69
SPECT-CT & PET-CT hybrids	69
Spectral CT	72
High field MRI	73
<b>Conclusions on imaging breakthroughs</b>	<b>75</b>

## **Chapter 3                      Challenges, opportunities & regulations                      78**

<b>Geographical challenges &amp; opportunities</b>	<b>80</b>
US market growth & legislative impact	80
International markets and changing dynamics	82
Urbanization and rise of the emerging markets	85
Patient demographics: therapeutic dynamics	87
<b>Technical Challenges &amp; Opportunities</b>	<b>89</b>
Molecular imaging	90
Molecular imaging probes	92
Regulatory support	93
Molecular imaging consortia	93
Imaging task forces	94

<b>Targeted and multifunctional imaging agents</b>	<b>96</b>
Nanotechnology	96
Nano-enabled delivery	97
Nano imaging materials	97
Targeted contrast agents	98
Multifunctional imaging agents	98
<b>Novel imaging modalities</b>	<b>99</b>
Magnetic Particle Imaging	99
PET-MRI	102
Real-time whole animal imaging	103
Multi-spectral opto-acoustic tomography	106
<b>Computer assisted imaging &amp; virtual surgery</b>	<b>107</b>
Virtual surgery	108
Breakthrough conclusions	109
<b>Reimbursement &amp; regulations</b>	<b>109</b>
<b>Overall conclusions</b>	<b>111</b>

## **Chapter 4                    Market trends & future directions 114**

<b>The medical imaging market</b>	<b>115</b>
Leading manufacturers of medical imaging equipment	116
<b>Leading healthcare companies</b>	<b>119</b>
GE Healthcare, New York, US	119
Hitachi Medical Corporation, Tokyo, Japan	119
Philips Medical Systems, Amsterdam, The Netherlands	120
Siemens Medical Solutions, Berlin & Munich, Germany	120
Toshiba Medical Systems Corporation, Tokyo, Japan	121
<b>M&amp;A activity</b>	<b>122</b>
<b>Recent market trends</b>	<b>125</b>
Global trends in medical imaging	125
Technological trends in imaging equipment	126
Imaging agents & nanotechnology	126
Image-guided radiation therapy and patient selection	127
<b>Future directions</b>	<b>128</b>
Molecular imaging & diagnostics	128
Medical imaging informatics and networking	129
Medical imaging and virtual reality	130
<b>Summary &amp; overall conclusions</b>	<b>131</b>

## **Chapter 5                    Appendices                    134**

<b>Primary research methodology</b>	<b>134</b>
-------------------------------------	------------

<b>Companies involved in medical imaging</b>	<b>135</b>
<b>Glossary</b>	<b>136</b>
<b>Acknowledgements</b>	<b>141</b>
<b>Index</b>	<b>142</b>
<b>Bibliography &amp; Endnotes</b>	<b>143</b>

# List of Figures

Figure 1.1:	Medical imaging uses a spectrum of wavelengths	17
Figure 1.2:	Medical imaging technologies	19
Figure 1.3:	Imaging techniques and their uses	22
Figure 1.4:	Medical imaging in the drug discovery & development process	24
Figure 1.5:	X-ray of a skull a) anterior-posterior and b) lateral view	27
Figure 1.6:	Computed tomography of the head a) coronal section and b) sagittal section	28
Figure 1.7:	X-ray imagers	29
Figure 1.8:	Evolution of CT imaging	30
Figure 1.9:	Magnetic resonance imaging of the head	31
Figure 1.10:	Functional magnetic resonance imaging of the brain	32
Figure 1.11:	Multispectral imaging of the arm (700-900 nm range)	33
Figure 1.12:	Ultrasound image of a baby in-utero	34
Figure 1.13:	Principles of PET imaging	36
Figure 1.14:	Fused PET/CT image of anatomy and function	37
Figure 1.15:	SPECT detection	39
Figure 1.16:	video imaging	40
Figure 1.17:	Therapeutic application of medical imaging	44
Figure 1.18:	Therapeutic applications of medical imaging	49
Figure 2.19:	Medical imaging workflow	54
Figure 2.20:	CT imaging artifacts	55
Figure 2.21:	US imaging artifacts	56
Figure 2.22:	US imaging artifacts	57
Figure 2.23:	Recent technological breakthroughs in medical imaging	61
Figure 2.24:	New scintillator materials	68
Figure 2.25:	Opportunities in PET & SPECT for better energy resolution	69
Figure 2.26:	Advances collimators focus and maximize SPECT-CT	70
Figure 2.27:	Schematic of Spectral CT technology	73
Figure 2.28:	Diffusion MRI - CNS	75
Figure 3.29:	Historical and future outlook of MR/CT revenues in the US (1997-2011)	81
Figure 3.30:	Global Population (2008)	86
Figure 3.31:	Population over 60: world and developed regions (1950-2050)	87
Figure 3.32:	Projected global deaths for selected conditions (2005-2030)	88
Figure 3.33:	Application of molecular imaging	91
Figure 3.34:	Delivery platforms for contrast agent	96
Figure 3.35:	Multifunctional agents	99
Figure 3.36:	Schematic of MPI technology	100
Figure 3.37:	IVIS Kinetic images in small animal models	106
Figure 3.38:	Real-time whole body optical imaging of Zebrafish	107

# List of Tables

Table 1.1:	Examples of image-related biomarkers with application in a variety of disease areas	26
Table 1.2:	Common PET positron-emitting tracer isotopes	35
Table 1.3:	Common SPECT radionuclides	38
Table 1.4:	Ex vivo imaging modalities	41
Table 1.5:	In vivo imaging modalities	42
Table 1.6:	Advantages & disadvantages of imaging modalities	43
Table 3.7:	Impact of American Recovery & Reinvestment Act (ARRA) on healthcare & medical imaging	82
Table 3.8:	Recent impact of investment & regulation on international healthcare & medical imaging markets	84
Table 3.9:	Typical effective radiation doses for medical imaging procedures	102
Table 3.10:	Leading manufacturers of small animal imaging equipment and probes	104
Table 4.11:	The medical imaging market – market leaders	115
Table 4.12:	Leading manufacturers of medical imaging equipment	117
Table 4.3:	Leading manufacturers of medical imaging equipment (cont)	118
Table 4.4:	Recent M&A activity in the medical imaging field	123
Table 4.5:	Recent M&A activity in the medical imaging field (continued)	124
Table 5.16:	The medical imaging market – leading companies in the US	135